Furthermore, studies have reported better immunotherapy prognosis in MSI-H GC patients, likely due to the high infiltration of CD8+ T cells, indicating a greater sensitivity to immunotherapy.[19] However, our study found that characteristics such as age, gender, previous surgery, primary location, liver metastases, ECOG performance status score, histological subtype, chemotherapy regimen, race, and PD-L1 expression in tumor cells did not predict clinical efficacy. This evidence concerns the gene CD8A and neoplasm.